Theses›Healthcare & bio›Pharma analytical instrumentation

Pharma analytical instrumentation

Two European entrants arrived in one quarter selling MEASUREMENT into a pharmaceutical workflow rather than a drug into a patient.

  • Bear
  • Early
  • $3.6B by 2035

The callFor 30 years every new measurement arrived as a module on a Thermo, Waters or Bruker box; only a platform sold outside their base could keep its own value.

D1D2R1R2R3C1foragainst D1D2R1R2R3C1foragainst
Fig. 1The balance. Drivers and catalysts against restraints, each block sized by its weight; catalysts hang dashed because they have not happened yet, sized by their odds. It tips toward the restraints.
  1. D1Drugs are becoming harder to measure: biologics, antibody-drug conjugates, radioligands with isotopes that decay in hours, AI-designed binders by the thousand.
  2. D2Installed mass specs were built for small molecules in central QC labs, so binding studies are slow and isotope release tests take hours while the dose decays.
  3. R1For 30 years new measurements have arrived as modules on an incumbent's platform; the best exit is Wyatt to Waters at $1.36B, about 12x revenue.
  4. R2The addressable slice is about $56M today and $130M by 2030 on a bottom-up sizing.
  5. R3Validating an instrument plus consumable in a regulated cGMP workflow costs an estimated $10-30M.
  6. C1The EMA or FDA writing a radiopharmaceutical release-testing requirement that names a method the incumbents do not ship; no date exists.undated
Rests onthe beliefs underneath
Supported by · confidence
What would prove itdated tests, open and resolved
20272028202920302031today12predictionswatch 20272028202920302031today12predictionswatch
Fig. 2Each ring is a dated test: dashed while open, struck through when overdue, ticked or crossed once resolved.
  1. 1Thermo Fisher, Waters, Agilent, Bruker, Danaher or Sartorius announces the acquisition of an analytical-instrument company founded after 2015 between 6 Nov 2026 and 31 Jan 2027.Jan 2027 · open
  2. 2The call, at 80%, that no European analytical-instrument entrant founded after 2020 discloses more than $50M of revenue from its own platform.Dec 2030 · open
  • ·Neither ionSIGHT nor LYLA, nor any European analytical-instrumentation entrant founded after 2020, discloses revenue above $50M from its own platform by 31 Dec 2030.
  • ·An EMA or FDA release-testing requirement naming a new method, which would change the radiopharma side.
Expressionslisted, private, technologies
  • TMOThermo Fisher Scientific
    • full
     Sells Orbitrap and triple-quad mass spectrometers, native-MS configurations, consumables and service to pharma discovery and QC labs.
  • WATWaters
    • not screened
     Sells LC-MS systems, chromatography consumables and (via Wyatt) light-scattering instruments for biologics characterisation and QC.
  • BRKRBruker
    • full
     Sells timsTOF and FTICR mass spectrometers and NMR systems to pharma for structural and binding analysis.
  • DHRSciex (Danaher)
    • fair
     Sells triple-quad and QTOF mass spectrometers and biopharma characterisation workflows to pharma labs; part of Danaher.
  • AAgilent Technologies
    • fair
     Sells LC-MS and GC-MS systems, consumables and service to pharma discovery and QC labs.
  • 7701.TShimadzu
    • not screened
     Sells LC-MS, GC-MS and chromatography systems to pharma QC and research labs.
Private · 5 private companies, 2 of them in the UK.

ILOF (Intelligent Lab On Fiber Limited) · ionSIGHT · Lyla · MOBILion Systems · Spectroswiss

Technologies
Who has already bet on itprivate rounds, from public sources

$110M raised by 4 companies. Wave building: Money is arriving: recent rounds and tier-1 funds are in, but no runaway leader yet.